Vaccination of melanoma patients with Melan-A/Mart-1 peptide and klebsiella outer membrane protein P40 as an adjuvant

Journal of Immunotherapy

Volumn 32, Issue 8, 2009, Pages 875-883

  Lienard, Danielle ^a,b   Avril, Marie Françoise ^d,f,g   Le Gal, Frédérique Anne ^c   Baumgaertner, Petra ^a   Vermeulen, Wim ^e   Blom, Astrid ^d,h   Geldhof, Christine ^a   Rimoldi, Donata ^a   Pagliusi, Sonia ^a   Romero, Pedro ^a   Dietrich, Pierre Yves ^c   Corvaia, Nathalie ^e   Speiser, Daniel E ^a  

^a Hopital Orthopedique de la Suisse Romande   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^f Hôpital Universitaire de Genéve ^*  (France)

^g INSTITUT COCHIN   (France)

^h AVICENNE HOSPITAL   (France)

Author keywords

CD8 T cells; Immune adjuvants; Immunotherapy; Peptides; Toll like receptor 2

Indexed keywords

ADJUVANT; GAMMA INTERFERON; MELAN A; OUTER MEMBRANE PROTEIN A; PROTEIN P40; TOLL LIKE RECEPTOR 2;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FATIGUE; FEMALE; FEVER; HEARING DISORDER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KLEBSIELLA PNEUMONIAE; MALAISE; MALE; MELANOMA; PAIN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; SKIN INDURATION; SKIN METASTASIS; SKIN NODULE; SKIN REDNESS; SKIN ULCER; VACCINATION; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HLA-A ANTIGENS; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; SKIN NEOPLASMS;

EID: 70349679081     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b56ad9     Document Type: Article

References (27)

1. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park). 1995;9:1149-1158; discussion 1163-1144, 1167-1168. Review.
2. Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer. 2001;84:1036-1042.
3. Kagi D, Ledermann B, Burki K, et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 1996;14:207-232. Review.
4. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12: 337-365. Review.
5. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230.
6. Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185-1192.
7. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J ExpMed. 1994;180:347-352. (Pubitemid 24181083)
8. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180:35-42. (Pubitemid 24181053)
9. Pittet MJ, Speiser DE, Lienard D, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res. 2001;7:796s-803s.
10. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
11. Valmori D, Fonteneau JF, Valitutti S, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol. 1999;11:1971-1980.
12. Lienard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4.
13. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746.
14. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998;90:1894-1900.
15. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer. 1996;66:162-169.
16. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
17. Speiser DE, Pittet MJ, Rimoldi D, et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol. 2003;13:461-472.
18. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
19. Jeannin P, Renno T, Goetsch L, et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol. 2000;1: 502-509.
20. Miconnet I, Coste I, Beermann F, et al. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol. 2001;166:4612-4619.
21. WHO. Handbook for reporting results of cancer treatment. Switzerland: World Health Organization Offset Publication; 1979:48.
22. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47:13-47.
23. Speiser DE, Pittet MJ, Guillaume P, et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother. 2004;27:298-308.
24. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998;188: 1641-1650.
25. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol. 2006;92:187-224.
26. Powell DJ Jr, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother. 2004;27:36-47.
27. Rauly I, Goetsch L, Haeuw JF, et al. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infect Immun. 1999;67:5547-5551.